The University of Oxford’s newly established Institute of Developmental and Regenerative Medicine (IDRM) is a unique flagship institution dedicated to meeting an ambitious challenge. Two thirds of all deaths world-wide are due to non-communicable diseases, many of which are cardiovascular, neurological or immune system disorders that have a developmental origin, representing an urgent unmet clinical need. Professor Paul Riley has been appointed Director of the IDRM to oversee programmes that will lead to the development of new drugs and therapeutic strategies to tackle these chronic illnesses. Notably, this will be brought about through a formal merger of developmental biology and regenerative medicine in the form of 220 world-leading cardiovascular, neuroscience and immunology researchers integrating their expertise to foster multidisciplinary collaborations. Alongside Professor Riley, the primary investigators will be Professor Georg A P Holländer (Hoffmann and Action Medical Research Professor of Paediatrics) and Professor Matthew Wood (Professor of Neuroscience).
Paul Riley appointed Director of Oxford’s Institute of Developmental and Regenerative Medicine
Awards and Appointments General
12 October 2020
Professor Paul Riley will lead the scientific vision of the first institute of its kind in the world to physically merge the disciplines of developmental biology and regenerative medicine in a common goal to treat some of the world’s most prolific diseases.